Abstract
1 Fifty patients with mild essential (primary) hypertension entered a double-blind, parallel-group study with either nicardipine 30 mg three times daily or placebo, randomly assigned as monotherapy for 6 weeks.
2 At the end of 6 weeks, the nicardipine-treated group had a statistically significant reduction in mean supine systolic/diastolic pressure of 21.2/15.0 mm Hg (P < 0.001) compared with the nonsignificant reduction of 0.7/2.9 mm Hg in the placebo-treated group. The difference in mean response between the nicardipine- and placebo-treated groups was significant (P < 0.001).
3 In the nicardipine-treated group, the reduction in mean standing systolic/diastolic blood pressure, 17.9/13.8 mm Hg, was significant (P < 0.001), whereas in the placebo-treated group the change was + 3.0 / - 1.5 mm Hg. The difference between the two treatment groups was significant (P < 0.001).
4 In both treatment groups, changes in pulse rate were minor, and there was no evidence of tachyphylaxis occurring with nicardipine. Adverse experiences were minor in all cases except for one patient with muscle pain during treatment with nicardipine.
5 Patients who received nicardipine showed a mean increase of 52% in plasma renin activity (PRA) after 6 weeks (P < 0.01). Initial basal or stimulated PRA did not correlate with blood pressure reduction on nicardipine.
6 Nicardipine 30 mg three times daily is a well-tolerated and effective antihypertensive agent.
Keywords: age, hypertension, nicardipine, plasma renin activity
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fyhrquist F., Soveri P., Puutula L., Stenman U. H. Radioimmunoassay of plasma renin activity. Clin Chem. 1976 Feb;22(2):250–256. [PubMed] [Google Scholar]
- Jones R. I., Hornung R. S., Sonecha T., Raftery E. B. The effect of a new calcium channel blocker nicardipine on 24-hour ambulatory blood pressure and the pressor response to isometric and dynamic exercise. J Hypertens. 1983 Jun;1(1):85–89. [PubMed] [Google Scholar]
- Koch-Weser J. Vasodilator drugs in the treatment of hypertension. Arch Intern Med. 1974 Jun;133(6):1017–1027. [PubMed] [Google Scholar]
- Lewis G. R., Morley K. D., Lewis B. M., Bones P. J. The treatment of hypertension with verapamil. N Z Med J. 1978 May 24;87(612):351–354. [PubMed] [Google Scholar]
- Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):343s–354s. doi: 10.1042/cs059343s. [DOI] [PubMed] [Google Scholar]
- Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
- Pedersen O. L., Mikkelsen E., Christensen N. J., Kornerup H. J., Pedersen E. B. Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol. 1979 May 21;15(4):235–240. doi: 10.1007/BF00618511. [DOI] [PubMed] [Google Scholar]
- Takabatake T., Ohta H., Yamamoto Y., Maekawa M., Arai S., Hattori N., Nomura G. Antihypertensive effect of nicardipine hydrochloride in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1982 Aug;20(8):346–352. [PubMed] [Google Scholar]
- Taylor S. H., Silke B., Ahuja R. C., Okoli R. Influence of nicardipine on the blood pressure at rest and on the pressor responses to cold, isometric exertion, and dynamic exercise in hypertensive patients. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):803–807. doi: 10.1097/00005344-198209000-00016. [DOI] [PubMed] [Google Scholar]
- Young M. A., Watson R. D., Littler W. A. Baroreflex setting and sensitivity after acute and chronic nicardipine therapy. Clin Sci (Lond) 1984 Feb;66(2):233–235. doi: 10.1042/cs0660233. [DOI] [PubMed] [Google Scholar]